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Abstract: Few treatment decision support interventions (DSIs) are available to engage patients
diagnosed with late-stage non-small cell lung cancer (NSCLC) in treatment shared decision making
(SDM). We designed a novel DSI that includes care plan cards and a companion patient preference
clarification tool to assist in shared decision making. The cards answer common patient questions
about treatment options (chemotherapy, chemotherapy plus immunotherapy, targeted therapy,
immunotherapy, clinical trial participation, and supportive care). The form elicits patient treatment
preference. We then conducted interviews with clinicians and patients to obtain feedback on the DSI.
We also trained oncology nurse educators to implement the prototype. Finally, we pilot tested the DSI
among five patients with NSCLC in treatment SDM at the beginning of an office visit scheduled to
discuss Treatment with an oncologist. Analyses of pilot study baseline and exit survey data showed
that DSI use was associated with increased patient awareness of the alternatives’ treatment options
and benefits/risks. In contrast, patient concern about treatment costs and uncertainty in treatment
decision making decreased. All patients expressed a treatment preference. Future randomized
controlled trials are needed to assess DSI implementation feasibility and efficacy in clinical care.
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1. Introduction
According to 2021 Cancer Statistics, lung cancer will account for 235,760 new cancer
cases and 131,880 cancer related deaths in the United States. The overwhelming majority
(84%) of new lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC).
Of those cases, 57% present with late-stage disease [1]. There are a number of treatment
options for patients with late-stage NSCLC, the mainstays of which are chemotherapy,
targeted treatment, and immunotherapy, palliative radiation and palliative surgery and supportive care, and clinical trial participation. Clinicians are trained to identify a personalized
treatment strategy based on a many factors, including patient age, health status, comorbidity profile, clinical presentation of disease, molecular and tumor characteristics, and
patient preference [2–7].
As part of determining a treatment plan, clinicians are encouraged to engage patients
in shared decision making (SDM) about recommended options [8–11]. Treatment SDM is
a patient-centered process in which the clinical team provides patients and caregivers with
information about the diagnosis, prognosis, and available treatment options; elicits patient
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values related to recommended treatment alternatives; clarifies personal preference related
to the options, and helps the patient choose an option that is consistent with personal goals
and optimal clinical care [12]. Decision support interventions (DSIs), which have also been
referred to as “decision aids”, can help to facilitate treatment SDM.
Historically, DSIs have been developed in educational booklets and videos designed
to present information about health care decisions to be made [13]. DSIs have also taken
the form of interactive computer-based or online software applications that provide patients with information about available health care alternatives and help patients clarify
their preferences [14]. Exposure to such DSIs in health care has been shown to increase
patient knowledge, reduce patient decisional conflict, and boost patient satisfaction with
care [15,16]. It has also been reported that DSI use can increase satisfaction with physicianpatient communication about treatment and ease patient anxiety about treatment decisionmaking among patients diagnosed with late-stage cancer [17].
Our current project aimed to (a) Perform a scoping review to identify DSIs developed
for use with patients diagnosed with late-stage NSCLC, (b) Develop a DSI that provides
patients with information about current treatment alternatives and elicits treatment preference, and (c) Assess DSI use in this patient population, and explore how DSIs can be
integrated effectively in routine care.
2. Materials and Methods
Following Coulter et al., the research team searched the literature to identify studies of
treatment SDM among patients diagnosed with lung cancer published from January 2000
to March 2020 [18]. This search involved searching databases: PubMed, Ovid (Medline),
and Google Scholar. We included original research articles (observational studies and
clinical trials) published in English. MeSH terms used to perform our search included:
‘shared decision making’, ‘lung cancer care’, ‘non-small cell’, ‘patient decision aid’, ‘systematic review’, ‘meta-analysis’ and ‘development’, ‘evaluation’ were included in the search
process. This effort initially yielded 29 publications that addressed SDM among patients
J. Pers. Med. 2021, 11, x FOR PEER REVIEW
3 of 13
diagnosed with lung cancer. Twenty-one reports did not focus on patients diagnosed with
NSCLC. Full-text analysis of the remaining eight reports that included patients with NSCLC
resulted in identifying two studies that evaluated DSI use among patients diagnosed with
late-stage NSCLC [14,17]. Details of this process are presented in Figure 1.

Figure 1. Studies of SDIs and SDM among Patients with non-small cell lung cancer (NSCLC).
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options for patients diagnosed with late-stage NSCLC. We also engaged a physician panel
and a patient panel to gain insights into provider and patient perceptions about the treatment SDM and utilization of the DSI prototype in practice.
2.2. Design Panel
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panel and a patient panel to gain insights into provider and patient perceptions about the
treatment SDM and utilization of the DSI prototype in practice.
2.2. Design Panel
This panel consisted of clinicians (two medical oncologists and two oncology nurses
involved in caring for NSCLC patients) and three researchers. Based on iterative discussions
about findings from the scoping review, design panel members decided it was essential
to develop a new type of DSI. This new DSI would provide basic information about
a range of treatment alternatives that answered patient questions, did not require patients
to read a lengthy document on available options and view a video recording, and could
be integrated into a clinical encounter. In addition, the panel agreed that it was essential
to develop a DSI prototype as a template for presenting treatment information that could
be modified to reflect emerging changes in treatment recommendations. Moreover, panel
members decided that a tool should be developed to record patients’ preferences related to
presented treatment options.
2.3. Physician Panel
Medical Oncologists from the Department of Medical Oncology at Thomas Jefferson
University Hospital were recruited to participate in a semi-structured in-person interview
on treatment shared decision making with patients diagnosed with late-stage NSCLC. In
the interview, participants were asked to describe what treatment alternatives they were
likely to recommend and how they helped patients make treatment decisions. In addition,
the interviewer explained the DSI prototype and asked for feedback on the utility of the
prototype and the feasibility of integrating the tool into clinical care.
All interviews were audio-recorded and transcribed. Interview transcripts from the
physician panel were coded independently by two members of the research team (SS
and PM) using NVivo 12 Pro (QSR International, Doncaster, Australia). Specifically, each
research team member evaluated each interview segment to identify and code initial subthemes, organize sub-themes into major themes, and ensure the major themes were unique.
The PI of the project (RM) met with research team members to resolve any differences in
sub-theme identification, coding, and organization.
2.4. Patient Panel
This panel included patients identified by the physician panel who were not enrolled
in the DSI pilot study. Eligibility criteria included being diagnosed with late-stage NSCLC
(either at baseline or recurring after surgery or radiation) and having had one of the
following treatment regimens: chemotherapy alone, chemotherapy and immunotherapy,
targeted therapy, or immunotherapy. Patients were excluded if they had comorbidity or
psychological factors that would contraindicate participation in the study or if a patient
was unable to provide informed consent or did not speak English.
For interested and eligible patients, in-person interview appointments were arranged.
Patients received a gift card for $50 after the interview for their participation and time.
The interviewer asked patients to describe their experience how they learned about their
diagnosis, treatment possibilities, and prognosis. In addition, the interviewer asked patients
to share what they learned and how they felt about their interactions with clinicians.
Patients were also asked to review each care plan card and treatment preference report
(which can be found in supplemental materials).
All interview transcripts from the patient panel were coded independently by two
members of the research team (SS and PM) using NVivo 12 Pro (QSR International,
Doncaster, Australia). The research team developed codes and identified significant themes
based on a review of interview transcripts. As with the physician interviews, each research
team member evaluated each interview segment to identify and code initial sub-themes, organize sub-themes into major themes, and ensure the major themes were unique. The PI of
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the project (RM) met with research team members to resolve any differences in sub-theme
identification, coding, and organization.
2.5. The Pilot Study
The research team planned to engage clinicians from the physician panel in identifying
and consenting patients for inclusion in a pilot study of the DSI prototype. Eligibility criteria
included patients who were 18 or more years of age, diagnosed with advanced NSCLC
(either at presentation or at first recurrence after surgery or radiation), could read and speak
English, and were approved by their oncologist for contact. Once a patient was deemed
eligible and was referred, a research assistant attempted to contact the patient by telephone
to explain the study, confirm eligibility, and assess their willingness to participate. If the
patient indicated an interest in the study, the next scheduled office visit was set to complete
study procedures.
Before the scheduled visit, each participant’s oncologist informed the research team
of the two major treatment options to be discussed at the visit. These treatment options
were evaluated by a Thomas Jefferson University financial advocate, who obtained specific
information about the patient’s current insurance plan, coinsurance, copay, and deductibles.
Using this information, the financial advocate provided the research team with estimated
participant out-of-pocket maximum costs related to the options. The research assistant entered this information into a personally tailored care plan card that described the treatment
options recommended for each participant and print two cards for each participant for use
by an oncology nurse in the decision counseling session. At the beginning of the office
visit, a study research assistant met each participant, reviewed study procedures, obtain
consent, and administer a baseline survey questionnaire.
The baseline survey included single items designed to elicit patient belief that treatment for late-stage NSCLC was likely to result in a cure, awareness that there was more than
one recommended treatment option for late-stage NSCLC, and concern about treatment
cost. Response options for each of these items were “Yes”, “No”, and “Unsure”. The survey
also included four items from the Decisional Conflict Scale [19], a measure used to assess
the respondent level of uncertainty related to the treatment of NSCLC. Scale questions
were: Do you feel sure about the best choice for you? Do you know the benefits and risks
of each option? Are you clear about which benefits and risks matter most to you? and Do
you have enough support and advice to make a choice? Participants could choose either
a “Yes” or “No” response to each question. Responses were summed, resulted in scores
that could range from 0 (extremely high decisional conflict) to 4 (no decisional conflict). In
this instance, a score of <3 indicates greater uncertainty about which treatment option is the
best choice, while a score of >3 indicates greater certainty about the best treatment choice.
Baseline survey items noted here were also included on an exit survey administered by the
research assistant at the end of the office visit.
After the research assistant administered the baseline survey, an oncology nurse
engage each participant in a 15–20-min decision counseling session. During this session,
the nurse review the two care plan cards with the participant and record participant
questions related to card content. Finally, the nurse elicited participant preference for
each treatment option (Prefer, Unsure, Do Not Prefer) and enter this information into the
preference report. One copy of the report was given to the patient, and another copy was
placed on the participant’s medical chart for review with their physician. After completing
the decision counseling session and before the physician-patient encounter, the research
assistant meet the patient and administered an exit survey. The exit survey included the
same single items to assess patient perceptions included in the baseline survey. The exit
survey also included the items used to determine baseline decisional conflict related to
treatment. Participants then went on the complete their physician-patient encounter. At
30 days, the research team completed a medical records review to determine participant
treatment status.
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3. Results
3.1. Scoping Review
In a study that involved 20 patients diagnosed with metastatic NSCLC, Leighl et al.
reported on participants who had completed an oncology visit at Princess Margaret Hospital in Canada [10]. Participants were provided a 25-page booklet that included information
about chemotherapy and available clinical trials, along with an audio-recording for use
at home. Another study conducted at the Ottawa Regional Cancer Center in Canada by
Fiset et al. involved 30 patients who were diagnosed with stage IV lung cancer and were
provided information about chemotherapy treatment by an oncologist [20]. Following
the clinic visit, a total of 20 patients agreed to review treatment information presented in
a booklet and an audio-recording. In these studies, most patients reported that receiving
treatment information in an informational booklet/audio-recording format was helpful in
treatment decision making (75% and 100%, respectively) [20].
As shown in Supplementary Table S1, both studies showed that patient treatment
knowledge increased significantly (p < 0.001) and patients reported favorably views of the
interventions. The Fiset et al. study showed that decisional conflict decreased significantly
(p < 0.001), and Leighl et al. reported that patient anxiety decreased (p = 0.04). Importantly,
these studies involved patients who were already undergoing treatment or had previously
discussed treatment with a clinician. In addition, the studies tested DSIs that provided
information in a self-guided fashion on a limited array of treatment options; and the DSIs
required patients to take action on their own to learn about treatment options. That is,
they tested DSI effects outside the context of a treatment consultation visit, rather than
testing the impact of providing information about treatment options as part of an oncology
consultation. Moreover, they addressed a very limited number of treatment options. Given
the changing increasing number of treatment alternatives available to patients with NSCLC,
there is a need for DSIs that can be used to facilitate treatment shared decision making
about current options [10,20].
3.2. Design Panel
The design panel developed a 1-page format called a “care plan card” to display
treatment options commonly offered by oncologists. A care plan card was developed for
each of six treatment options, including: chemotherapy, chemotherapy and immunotherapy, immunotherapy, targeted therapy, clinical trial participation, and supportive care.
In addition, panel members identified a set of common questions patients asked about
treatment and agreed on simple answers to each question. The cards included answers to
the following questions: (1) What can I expect from the Treatment? (2) What agent(s) will I
receive? (3) Will my symptoms be treated? (4) Will I be offered radiation or minor surgery if
it could relieve my symptoms? (5) How often do I get Treatment? (6) How often will I need
X-rays or CT scans? (7) How often will I need blood tests? (8) What are the side effects?
(9) What is the out-of-pocket cost of Treatment? A generic response to questions 1–8 was
included, along with an open-ended response to question 9 that was intended to be specific
to each patient’s insurance coverage. The design panel also developed a 1-page report
referred to as a treatment preference report to augment the care plan cards. This document
allowed the patient to choose one of the following responses for each treatment option
presented: Prefer, Undecided, and Do Not Prefer. Patient responses could be recorded on
the report, along with any questions the patient may want to ask the physician during the
ensuing physician-patient encounter. These tools are included as Supplementary Materials.
3.3. Physician Panel
Clinicians (N = 9) were recruited and interviewed. Four themes emerged from these
interviews: (1) Tailoring treatment to the patient; (2) Physician-patient communication;
(3) Engaging members of the clinical team, and (4) Integrating DSIs into clinical care.
In regard to the first theme, respondents highlighted the importance of tailoring
treatment plans to an individual’s unique physical and clinical characteristics. For example,
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Physician 6 noted, “Some patients have other problems such as rheumatoid arthritis
and ulcerative colitis, which can color the decision to use immunotherapy because the
risk is a bit higher. . . so, you need to know other things about the patient to make the
best decision”. Physician 8 also illustrated this point by saying, “For lower performance
status, the patient may be more likely to develop toxicity from the therapy, and therefore,
chemotherapy may pose more of a risk to that person. Therefore, the consideration for
immunotherapy alone or supportive care should at least be considered and discussed. . . ”
Another respondent (Physician 3) highlighted the increasing importance of genetic test
results in clinical decision making, “I think the genetic mutations are the things we’re
looking for more and more these days. I think that’s—focuses more towards targeted
therapies. The targeted therapies can be very helpful in the patient’s individual situation
and result in some pretty dramatic responses with treatment”.
For the second theme, most physicians reported that establishing good physicianpatient communication involves both providing information and asking about the patient’s
treatment goals. As explained by Physician 2, “educating the patient, married with identifying patient goals, especially related to having an acceptable quality of life, is the way
that a medical decision is arrived at, so that it is able to fit both sides of that equation”.
Physician 6 also noted, “most patients would want to hear from their physician what the
disease is, how the disease might be treated, whether or not they have a mutation and in
general about the treatment”. Physician 9 noted, “I. . . talk to (patients) about the risks and
benefits, what toxicity there is between the different options, and talk about what their
preferences are, what their goals of therapy are”. Another physician (5) commented, “I
think that’s important for patients when they’re having a difficult time deciding whether to
take active treatment if they have a poor physical status or fairly significant tumor burden
(then) having further knowledge of expected outcomes with the treatment can shape better
expectations and help the decision for the patient”. Several physicians mentioned the need
to address the role of family members, especially with patients for whom supportive care
is recommended as an option to consider.
For the third theme, physicians acknowledged that nurses and other oncology team
members could play an important role in SDM. As expressed by Physician 6, “. . . most
patients would want to hear from their physician what the disease is, how the disease
might be treated, whether or not they have a mutation and in general about the treatment”.
However, an oncology nurse, a nurse practitioner, or social worker on the care team could
help to address patient needs for additional information, “. . . if people are asking a little
bit more about side effects or practical stuff like that, then I think it needs to be someone
that has some knowledge about that. . . a person that had some additional education about
those options. . . whether it’s a nurse, or a research coordinator, or a social worker”.
Lastly, in regards to the fourth theme, respondents thought that implementation of
the DSI with patients could be useful after the physician decided on a treatment in order
to increase patient understanding and adherence but were unsure about how/when the
use of the tool could be integrated into clinical care. As noted by Physician 7, “. . . it (DSI
use) shouldn’t be at the first (visit). . . when the patient’s given the diagnosis. It should be
after the diagnosis has been given (in) the evaluation period”. Physician 1 recommended,
“Well, I think. . . the patient may wish to take it (results of the DSI session) home and think
about it for some time. I think it may be helpful to have sort of a telephone follow-up. . . in
expediting the next steps in treatment”.
3.4. Patient Panel
Ten patients were interviewed. The patient interview transcripts resulted in the identification of three major themes: (1) Patient and caregiver involvement, (2) Physician-patient
communication, (3) Engaging members of the clinical team, and (4) Integrating DSIs into
clinical care.
Regarding Patient Theme 1, patients commonly reported that a family member or
friend accompanied them to their office visits, and they explained that these caregivers
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play an important role in helping them understand information imparted by the clinician.
One patient (Patient 3) noted, “My husband was with me every step of the way”. Patient 4
said, “(The physician) laid out this—the original protocol, which is the one I’m doing. And
then that was the one. We picked this one because I wanted to have a (good) quality of life”.
In some cases, however, patients felt that the process of engaging caregivers in treatment
decision making was suboptimal. As noted by Patient 7, “We (patient and caregiver) would
be presented with the information from the provider. He allowed us to ask questions. And,
the questions weren’t necessarily answered with the information that we needed to feel
like we were empowered”.
For theme 2, patients commonly reported that physician-patient communication
tended to focus on the diagnosis, test results, a recommended treatment approach, and
deciding on whether or not to follow the recommendation. Patient 6 described the process
as follows, “(The doctor) explains to the patient, okay, this is what you’re seeing, this is what
we found out, and this is what all the tests—the conclusions to all the tests were. And now,
together, we both need to make a decision”. As described by Patient 1, this process varies by
the physician as, “Some physicians explain everything in words, verbally. Some physicians
give printed materials to read. Different physicians do this differently”. Many patients
pointed out that physicians need to use different communication methods to ensure patient
understanding. In this regard, patient 6 explained that to be successful in communicating
with patients, “The doctor (has) to understand a person’s level of intelligence. . . you (can’t)
make it too technical, because a person might not understand it. You’d have to be able to
make it where the person feels comfortable. . . ”
For the third theme, patients viewed their interactions with the clinical team as quite
important, especially those that took place with oncology nurses at the time of their office
visit. Patient 3 explained, “. . . I tell you, you have to have a special nurse to be able to
have the knowledge and maintain the relationship, doctor/patient, nurse/patient, two
different things”. To optimize care, patient 3 highlighted the importance of the nursing
staff as follows, “It’s gotta be the special nurse that has it in her heart to be able to relate
and have empathy for the one who has cancer”. Patient 4 commented on the role of nurses
on the clinical team as follows, “And having the nurses involved in helping to explain
things that are going to happen. . . . she also knows the medicine and the pros and cons,
because I think that’s what they get taught”.
Lastly, for the fourth theme, patients expressed that it was essential to making the
tool available as part of the treatment decision making. In this regard, Patient 3 said that
the use of a DSI would help to engage patients in the treatment decision making process,
“Rather than just say this is what you have to do, we want you to be part of that process of
understanding and deciding”. Regarding the option cards, another patient (Patient 6) said,
“You should get this card when you initially meet with the doctor, so you will know what
to expect. So, if you decide to change your mind. . . at least you know what you’re facing”.
Another patient commented on the cards’ informational content, noting that treatment
is intended to increase the length and quality of life. I think that’s good to get that right
out in front and to explain the side effects”. Patient reactions to the summary report were
also positive, as noted by Patient 6, “Because it’ll give the patient something to look at,
visually . . . And it would allow your doctor to explain to the patient, (and) make his own
decision, too”.
Major themes identified through interviews conducted with physician panel and
patient panel participants are summarized in Table 1.
Table 1. Themes identified in interviews with physician and patient panel members.
Physician Panel Themes

Patient Panel Themes

Tailoring Treatment to the patient
Physician-patient communication
Engaging members of the clinical team
Integrating DSIs in clinical care

Patient and caregiver involvement
Physician-patient communication
Engaging members of the clinical team
Integrating DSIs in clinical care
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3.5. The Pilot Study
The research team worked with medical oncologists currently involved in treating
late-stage NSCLC to identify and consent patients in a pilot study of the DSI prototype.
N = 5 patients were recruited and completed all study tasks.
3.5.1. Demographic Characteristics
Table 2 shows that among study participants, three were female, four were white,
and one was African American. Two participants were married, and two had a high
school education.
Table 2. Participant background characteristics (N = 5).
Characteristic

Category

N

%

Sex

Female
Male

3
2

60.0
40.0

Race

Black or African American
White

1
4

20.0
80.0

Ethnicity

Not Hispanic or Latino

5

100.0

Marital Status

Married
Single
Widowed

2
2
1

40.0
40.0
20.0

Education

Less than a High School Diploma
High School Diploma
Some College or Associate Degree
Bachelor’s Degree
Master’s Degree or higher

0
2
2
1
0

0.0
40.0
40.0
20.0
0.0

3.5.2. Change in Perceptions about Treatment
Data presented in Table 3 shows that at baseline, two participants believed that
treatment was likely to result in a cure, one did not think that a cure was possible, and
two were unsure. Findings from the exit survey indicate that one of the participants who
were uncertain about the likelihood of a cure reported that a cure was unlikely. At baseline,
only two participants stated that they knew what treatment options were available to them.
Still, at the time of the exit survey, all participants reported that they were aware of their
treatment options. At baseline, three participants expressed concern about treatment cost,
but only one said this concern on the exit survey.
Table 3. Change in perceptions about treatment (N = 5).
Variable

Belief in Cure From Treatment

Awareness of Treatment Options

Concern about Treatment Costs

Baseline Survey

Exit Survey

Yes

2

2

No

1

2

Unsure

2

1

Yes

2

5

No

1

0

Unsure

2

0

Yes

3

1

No

2

3

Unsure

0

1

3.5.3. Change in Decisional Conflict about Treatment
Table 4 shows that at baseline, participants had a mean decisional conflict scale score
of 2.2, which indicates uncertainty about which treatment option was preferred. On the exit
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survey, participants reported a mean decisional conflict score of 3.2, indicating that their
level of decisional conflict was reduced, and they felt more certain about their preferred
treatment choice.
Table 4. Participant certainty in treatment decision making (N = 5).
Variable

Mean Baseline Survey Score

Mean Exit Survey Score

Change

Decisional Conflict Scale

2.2

3.2

+1.0

A mean scale score of <3 indicates a low level of certainty in decision making, while a mean score of >3 indicates
a high level of certainty in decision making. A positive change score indicates increased certainty.

3.5.4. Recommended Treatment Options, Treatment Preference, and Treatment Status
As indicated in Table 5, each participant was offered a different combination of treatment
options. The recommended treatment option was as follows: Participant 1—chemotherapy
and immunotherapy or immunotherapy; Participant 2—chemotherapy and immunotherapy or
chemotherapy; Participant 3—immunotherapy or a clinical trial; Participant 4—chemotherapy
or a clinical trial; and Participant 5—immunotherapy or supportive care. Participant treatment
preferences recorded after the nurse-guided decision counseling session were: Participant
1—chemotherapy and immunotherapy; Participant 2—chemotherapy and immunotherapy;
Participant 3—immunotherapy; Participant 4—chemotherapy alone; and Participant 5—
immunotherapy. At 30 days after the office visit, a review of medical records indicated that
Participant 1 had not made a treatment decision; Participant 2 was undergoing chemotherapy and immunotherapy, Participant 3 enrolled in a clinical trial, and Participants 4 and 5
received chemotherapy.
Table 5. Recommended treatment options, preference, and status at 30 days.
Participant

Treatment Option 1

Treatment Option 2

Treatment Preference

Treatment Status

1

Chemotherapy and Immunotherapy

Immunotherapy

Chemotherapy and Immunotherapy

Undecided

2

Chemotherapy and Immunotherapy

Chemotherapy

Chemotherapy and Immunotherapy

Chemotherapy and
Immunotherapy

3

Immunotherapy

Clinical Trial

Immunotherapy

Clinical Trial

4

Chemotherapy

Clinical Trial

Chemotherapy

Chemotherapy

5

Immunotherapy

Supportive Care

Immunotherapy

Chemotherapy

4. Discussion
When we initiated this study, there were a small number of published reports on
DSIs that had been developed for use with patients diagnosed with NSCLC. We discovered that existing DSIs focused on a small number of treatment options. In addition, the
tools provided a substantial amount of complex information either in print form or online
that answered a limited range of patient questions. In addition, published reports did
not focus on the role clinical team members could play in preparing patients and family
members for shared treatment decision-making. We sought to address these issues by
developing a 1-page care plan option card, each of which provided generic answers concisely to questions asked by patients. The cards were tailored for individual patients by
providing information on potential out-of-pocket costs related to care. This DSI allowed
clinicians to select treatment options they planned to discuss with their patients and allowed patients to gain insight into the nature of those options before the physician-patient
encounter. Oncology nurses also guided patients through a simple exercise to elicit patient
treatment preference.
This DSI prototype differs from others reported in the [10,20] in several respects. First,
the care plan option cards are designed to provide basic information about the range of
treatment options available to patients. Second, basic information on the cards is generically
presented and easy to understand, especially when the presentation is guided by a nurse
or other oncology team member. Third, information on the card can be tailored to address
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specific patient concerns, such as treatment-related costs. Furthermore, this patient and
family member education process is augmented by engaging oncology nurses in guiding
patients through a brief preference clarification exercise, which can be made available
immediately to patients and providers to determine a course of treatment that makes
sense to patients and providers. In our view, this type of DSI is relatively simple, can be
adapted for use in various practice settings, and is feasible for integration into the clinical
workflow. Notably, the DSI also serves to engage the clinical team in the treatment shared
decision-making process.
In the pilot study, we found that oncologists embraced the opportunity to identify
care plan option cards for review by patients before an ensuing patient encounter; oncology nurses were able to review selected cards with patients and family members at the
beginning of a clinic visit. Our study found that using the DSI prototype was feasible
while the patient was waiting for their oncologist consultation. We also determined that
deployment of the DSI prototype had beneficial effects on knowledge and perceptions
related to treatment decision-making in a subset of patients included in the pilot study.
The provision of simple care plan cards enabled patients to learn basic information about
treatment alternatives from an oncology nurse on the care team before consulting with
an oncologist.
The potential value of deploying such interactive DSIs for patients with advanced
cancer is highlighted by findings reported in a systematic review by Spronk et al. The
study team reviewed DSIs explicitly developed for use among patients diagnosed with colorectal cancer and lung cancer [21]. In one report, Dubenske et al. described an interactive
web-based communication system for patients with advanced lung cancer and family
members that provided patients access to information about treatment alternatives, enabled patients to clarify personal treatment preference, and generated a summary report
for clinicians. They found that patients guided through this DSI reported a more significant reduction in symptom distress than controls [22]. In another report, Meropole et al.
tested a web-based DSI designed to help patients with advanced cancer clarify treatment
preference and train patients to discuss treatment options with their provider. Following
clinical consultation, patients exposed to this type of DSI reported greater satisfaction with
physician communication and treatment decision-making than controls [23].
Our study found that using the DSI prototype was feasible, as it required ~15 min in
the waiting room or while the patient was waiting for their oncologist consultation. As
described above, we also determined that deployment of the DSI prototype had beneficial
effects on knowledge and perceptions related to treatment decision making in a subset of
patients included in the pilot study.
Integrating DSI use in routine care will involve eliciting recommended treatment
options from clinicians before the patient visit and training nurses and other allied staff
in DSI use. Oncologists in our study were amenable to identifying treatment alternatives
they planned to discuss with their patients, and oncology nurses were enthusiastic about
the opportunity to engage patients in a structured review of these options. We believe that
the importance of nurse-patient interactions that facilitate patient education in cancer care
will grow [24]. In this regard, team care in oncology will be critical in addressing gaps in
patient and family member needs. Moreover, team-based care can also help facilitate access
to information and engagement in decision-making about initial treatment and subsequent
treatment, rehabilitation, and survivorship care [25–27].
Regarding study limitations, we developed and piloted the implementation of a DSI in
only one oncology practice setting. Additionally, we did not observe the physician-patient
interaction, which led to the 30-day treatment status of participants. In addition, the pilot
study included only a small number of patients in the study, and, as a result, we could
not conduct statistical analyses of DSI effects. Furthermore, the DSI included information
about the range of treatment options. Given the dynamic nature of treatment research, it is
clear that care plan cards included in the DSI will need to be updated following changes
in the evolution of treatment guidelines. It is essential to point out that randomized
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studies involving more significant numbers of patients and conducted in various practice
settings are needed. Such efforts should include adapting and developing care plan option
cards that provide patients with basic information about treatment options that evolve in
personalized care. Moreover, research is needed to illuminate interactions that take place
between a well-informed patient who has expressed a treatment preference and clinicians
who embrace shared decision making.
5. Conclusions
This project aimed to develop a novel, patient-friendly DSI that can be integrated
into routine care. The DSI described here was implemented in real-time in the clinic
through collaboration with oncology nurses. We showed it helped patients with newly
diagnosed advanced NSCLC prepare for treatment decision-making in the physicianpatient encounter. Further research is needed to evaluate DSI implementation in more
extensive and more diverse patient populations and different practice settings. Such studies
should be designed to illuminate intervention effects on patient treatment knowledge,
decisional conflict, preference, and choice.
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